- 作者：Yun-xin Zhang ; Li Wang ; Peng-yu Ji ; Gang-gang Zhao ; Gan-ping Zhong ; Zhi-ping Wang
- 关键词：Prostate cancer ; ¦Â2-microglobulin ; Clinical pathology ; Prognosis ; Metastasis
- 刊名：Archives of Medical Research
- 出版年：2013
- 出版时间：May, 2013
- 年：2013
- 卷：44
- 期：4
- 页码：259-265
- 全文大小：225 K
Background and Aims
Despite previous reports implying a role of ¦Â2-microglobulin (¦Â2M) in the development of prostate cancer (PCa), the correlation of serum ¦Â2M with the clinicopathological features, therapy efficacy and prognosis of patients with PCa have not been fully clarified. The present study aims to investigate the serum levels of ¦Â2M in patients with PCa and explore the potential use of ¦Â2M as a tumor marker for diagnosis, treatment and prognosis of PCa.Methods
Serum ¦Â2M levels in 120 patients with PCa, 50 patients with benign prostate hyperplasia (BPH) and 85 healthy age-matched controls were measured by enzyme immunoassay. The correlation of serum ¦Â2M with the clinicopathological features, therapy efficacy and the prognosis of PCa were subsequently assessed.
Results
Our results showed that: (i) PCa patients had significantly higher levels of ¦Â2M compared to those of patients with BPH or those of healthy controls. (ii) Serum ¦Â2M were markedly elevated in patients with high stage or grade PCa as compared to patients with low stage or grade PCa. (iii) We measured significantly higher levels of ¦Â2M in patients with metastasis as compared to patients lacking metastasis. (iv) During follow-up, serum ¦Â2M showed a marked decrease after successful therapy and a significant further increase in recurrent disease.
Conclusions
Our results demonstrate that serum ¦Â2M is correlated closely with the clinical stage, Gleason grade, PSA, distant metastasis and therapy efficacy in patients with PCa. Serum ¦Â2M may be a useful biomarker for clinical diagnosis, follow-up and prognosis of PCa.